Jason Fangusaro, MD

Research Program

Discovery and Developmental Therapeutics
Phone Number

404-785-1112
Email Address

jfangus@emory.edu

Biography

Jason Fangusaro, MD, is director of Developmental Therapeutics at the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta. Dr. Fangusaro is also Professor of Pediatrics at the Emory University School of Medicine and the Carter S. Martin Endowed Chair. As a clinical member of the pediatric neuro-oncology team, he specializes in treating children with central nervous system malignancies, including brain and spinal cord tumors. He is a is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University in Atlanta, Georgia.

Education

Dr. Fangusaro received his MD from Loyola University Stritch School of Medicine in Chicago, Illinois. He did his residency at Lutheran General Children's Hospital in Chicago, Illinois. He completed a Pediatric Hematology/Oncology Fellowship at Nationwide Children's Hospital in Columbus, Ohio, and a Pediatric Neuro-Oncology Fellowship at Children's Hospital of Los Angeles in California.

Titles & Roles

Professor, Department of Pediatrics

Emory University School of Medicine
Director of Developmental Therapeutics

Aflac Cancer and Blood Disorders Center

Professional Memberships

Dr. Fangusaro is a member of the Children's Oncology Group Brain Tumor Steering Committee, serves as the vice chair of the Pediatric Brain Tumor Consortium and partners with the pharmaceutical industry on investigator-initiated trials. He holds professional memberships with American Society of Clinical Oncology, Society for Neuro-Oncology and Children's Oncology Group.

Research

Dr. Fangusaro's primary area of research is the development of early phase clinical trials, novel therapeutics and relevant biologic correlates in an effort to improve survival outcomes and minimize toxicities. Within pediatric brain tumors, his research has focused on two main areas: low grade gliomas (LGG) and central nervous system (CNS) germ cell tumors (GCTs).

He is a member of both the LGG and CNS GCT international consensus panels, and also serves as the principal investigator and co-investigator on numerous national trials.

View Current Clinical Trials


A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration Phase I Conditions Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1 Location Winship Cancer Institute
Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery Phase I Conditions Medulloblastoma, Childhood, Medulloblastoma Recurrent, Medulloblastoma Location Winship Cancer Institute
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma Phase II Conditions Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Neurofibromatosis Type 1, Recurrent Visual Pathway Glioma, Refractory Neurofibromatosis Type 1, Refractory Visual Pathway Glioma Location Winship Cancer Institute
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma Phase II Conditions Basal Ganglia Germinoma, Central Nervous System Germinoma, Diabetes Insipidus, Pineal Region Germinoma, Suprasellar Germinoma, Thalamic Germinoma
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy Phase I Conditions Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia, Refractory Childhood Acute Myeloid Leukemia, Refractory Childhood Myelodysplastic Syndrome, Refractory Juvenile Myelomonocytic Leukemia
A Study of Avutometinib for People With Solid Tumor Cancers Phase I Conditions Refractory Cancer, CNS Tumors, CNS Tumor, Adult, CNS Tumor, Childhood, MAP Kinase Family Gene Mutation, NF1, Plexiform Neurofibroma, Low-grade Glioma, Optic Pathway Gliomas, Neuroblastoma, Primary Brain Tumor, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, Central Nervous System Tumor
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors Phase I Conditions Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma, Malignant Solid Neoplasm, Poorly Differentiated Chordoma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Chordoma, Recurrent Epithelioid Sarcoma, Recurrent Kidney Medullary Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Rhabdoid Tumor, Refractory Atypical Teratoid/Rhabdoid Tumor, Refractory Chordoma, Refractory Epithelioid Sarcoma, Refractory Kidney Medullary Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Rhabdoid Tumor, Rhabdoid Tumor
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma Phase I Conditions Diffuse Midline Glioma, H3 K27-Altered, Metastatic Malignant Neoplasm in the Central Nervous System, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27-Altered, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Primary Malignant Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Primary Malignant Central Nervous System Neoplasm Location Winship Cancer Institute
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT Phase II Conditions Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma, Malignant Teratoma, Mixed Germ Cell Tumor, Pineal Region Germ Cell Tumor, Pineal Region Immature Teratoma, Pineal Region Yolk Sac Tumor, Suprasellar Germ Cell Tumor Location Winship Cancer Institute
Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma Phase II Conditions Osteosarcoma, Recurrent Osteosarcoma Location Winship Cancer Institute
A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma Phase III Conditions Recurrent Low Grade Astrocytoma, Recurrent WHO Grade 2 Glioma, Refractory Low Grade Astrocytoma, Refractory Low Grade Glioma, Refractory WHO Grade 1 Glioma Location Winship Cancer Institute
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma Phase III Conditions Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma, Metastatic Low Grade Glioma, WHO Grade 1 Glioma, WHO Grade 2 Glioma Location Winship Cancer Institute
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma Phase III Conditions Low Grade Glioma, Neurofibromatosis Type 1, Visual Pathway Glioma Location Winship Cancer Institute

Publications

Title/Journal	Authors	Publication Date
Artificial Intelligence for Response Assessment in Pediatric Neuro-Oncology (AI-RAPNO), part 1: review of the current state of the art The Lancet Oncology	BH Kann, A Vossough, SC Brüningk, AM Familiar, M Aboian, MG Linguraru, KW Yeom, SM Chang, D Hargrave, D Mirsky, PB Storm, RY Huang, AC Resnick, M Weller, S Mueller, M Prados, AC Peet, JE Villanueva-Meyer, S Bakas, J Fangusaro, A Nabavizadeh, AF Kazerooni	10/28/2025
Artificial Intelligence for Response Assessment in Pediatric Neuro-Oncology (AI-RAPNO), part 2: challenges, opportunities, and recommendations for clinical translation The Lancet Oncology	AF Kazerooni, AM Familiar, M Aboian, SC Brüningk, A Vossough, MG Linguraru, RY Huang, D Hargrave, AC Peet, AC Resnick, PB Storm, D Mirsky, KW Yeom, M Weller, M Prados, SM Chang, S Mueller, JE Villanueva-Meyer, S Bakas, J Fangusaro, BH Kann, A Nabavizadeh	10/28/2025
Diffuse leptomeningeal glioneuronal tumor (DLGNT): a comprehensive clinical and molecular analysis Acta Neuropathologica	MK Mikkelsen, X Li, K Yu, AA High, H Tan, LV Furtado, N Leelatian, J Bell, JD Berry, DR Boué, F Chien, SL Coven, MC Dewan, J Fangusaro, JB Foster, L Hoffman, JK Kofler, T Larkin, M Lazow, A May, BC Mobley, D Noun, B Posorske, J Schwartz, I Sheila, S Spiller, R Tanaka, I Qaddoumi, CL Tinkle, J Peng, GW Robinson, DC Moreira, J Chiang	08/11/2025
Response Assessment in Neuro-Oncology (RANO) 2009–2025: Broad scope and implementation—A progress report Neuro-Oncology	MJ van den Bent, MA Vogelbaum, T Cloughesy, N Galldiks, NL Albert, JC Tonn, E Avila, J Fangusaro, D Mirsky, A Sahgal, R Soffietti, P Karschnia, M Mehta, MM Kim, F Boele, JT Huse, L Nayak, MJ Lim-Fat, E le Rhun, A Desjardins, EQ Lee, U Chukwueke, JAF Koekkoek, T Mendoza, AR Loughan, JA Budhu, S Bakas, RY Huang, JE Villanueva-Meyer, JP Leone, H Okada, DA Reardon, WL Bi, PY Wen, SM Chang	05/03/2025
A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4 Neuro-Oncology	J Fangusaro, A Onar-Thomas, T Young Poussaint, S Lensing, AH Ligon, N Lindeman, A Banerjee, LB Kilburn, A Lenzen, N Pillay-Smiley, IF Pollack, NJ Robison, S Partap, I Qaddoumi, D Landi, DTW Jones, CF Stewart, M Fouladi, IJ Dunkel	04/17/2025
BRAF inhibitor monotherapy in BRAFV600E-mutated pediatric low-grade glioma: a single center’s experience Frontiers in Oncology	SS McThenia, KM Reddy, E Damaraju, E Castellino, Z He, R Beers, F Chien, RC Castellino, AE Goldman-Yassen, JR Fangusaro, T MacDonald	01/07/2025
Head-to-head preclinical treatment design prioritizes promising therapies for neurofibromatosis type 1 optic glioma clinical translation. Neuro-oncology advances	T Eligator, J Chatterjee, S Yamada, A Kirchner, HB Nair, JR Fangusaro, DH Gutmann	01/01/2025
Pediatric neuro-oncology: Highlights of the last quarter-century Neoplasia	P Power, JP Straehla, J Fangusaro, P Bandopadhayay, N Manoharan	12/05/2024
Pediatric metastatic extracranial high-grade glioma: A case report and literature review Neuro-Oncology Practice	N Ali, BR Eaton, JR Fangusaro, RC Castellino, JE Velázquez Vega, JJ Chern, M Schniederjan, P Patil	10/03/2024
Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directions Neuro-Oncology	MJ Lim-Fat, J Bennett, Q Ostrom, M Touat, E Franceschi, J Schulte, RS Bindra, J Fangusaro, G Dhall, J Nicholson, S Jackson, TB Davidson, G Calaminus, G Robinson, JR Whittle, P Hau, V Ramaswamy, KW Pajtler, R Rudà, NK Foreman, SL Hervey-Jumper, S Das, P Dirks, WL Bi, A Huang, TE Merchant, M Fouladi, K Aldape, MJ Van den Bent, RJ Packer, JJ Miller, DA Reardon, SM Chang, D Haas-Kogan, U Tabori, C Hawkins, M Monje, PY Wen, E Bouffet, KK Yeo	09/13/2024
Towards consistency in pediatric brain tumor measurements: Challenges, solutions, and the role of artificial intelligence-based segmentation Neuro-Oncology	AM Familiar, A Fathi Kazerooni, A Vossough, JB Ware, S Bagheri, N Khalili, H Anderson, D Haldar, PB Storm, AC Resnick, BH Kann, M Aboian, C Kline, M Weller, RY Huang, SM Chang, JR Fangusaro, LM Hoffman, S Mueller, M Prados, A Nabavizadeh	05/21/2024
Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions—International Pediatric Low-Grade Glioma Coalition Neuro-Oncology	P O'Hare, T Cooney, P de Blank, DH Gutmann, M Kieran, T Milde, J Fangusaro, M Fisher, S Avula, R Packer, K Fukuoka, K Mankad, S Mueller, AJ Waanders, E Opocher, E Bouffet, E Raabe, NE Werle, AA Azizi, NJ Robison, P Hernáiz Driever, M Russo, N Schouten, CM van Tilburg, A Sehested, J Grill, P Bandopadhayay, JP Kilday, O Witt, DM Ashley, BB Ertl-Wagner, U Tabori, DR Hargrave	05/14/2024
Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma Clinical Trials: An FDA Educational Symposium Clinical Cancer Research	J Fangusaro, RA Avery, MJ Fisher, RJ Packer, KS Walsh, A Schouten-van Meeteren, D Karres, D Bradford, V Bhatnagar, H Singh, PG Kluetz, M Donoghue, ES Duke	02/15/2024
Primary Diffuse Leptomeningeal Melanomatosis in a Child with Extracranial Metastasis: Case Report Current Oncology	SW Shahab, P Patil, JR Fangusaro, B Patteson, A Goldman-Yassen, BR Eaton, W Boydston, M Schniederjan, D Aguilera	01/20/2024
Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group Neuro-Oncology	S Mueller, J Fangusaro, AO Thomas, TS Jacques, P Bandopadhayay, P de Blank, RJ Packer, M Fouladi, AS van Meeteren, D Jones, A Perry, Y Nakano, D Hargrave, D Riedl, NJ Robison, M Partanen, MJ Fisher, O Witt	12/26/2023
Pediatric low-grade glioma: State-of-the-art and ongoing challenges Neuro-Oncology	J Fangusaro, DT Jones, RJ Packer, DH Gutmann, T Milde, O Witt, S Mueller, MJ Fisher, JR Hansford, U Tabori, D Hargrave, P Bandopadhayay	11/07/2023
Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation Neuro-Oncology	T Milde, J Fangusaro, MJ Fisher, C Hawkins, FJ Rodriguez, U Tabori, O Witt, Y Zhu, DH Gutmann	09/21/2023
Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial Neuro-Oncology	TS Johnson, TJ MacDonald, R Pacholczyk, D Aguilera, A Al-Basheer, M Bajaj, P Bandopadhayay, Z Berrong, E Bouffet, RC Castellino, K Dorris, BR Eaton, N Esiashvili, JR Fangusaro, N Foreman, D Fridlyand, C Giller, IM Heger, C Huang, N Kadom, EP Kennedy, N Manoharan, W Martin, C McDonough, RS Parker, V Ramaswamy, E Ring, A Rojiani, RF Sadek, S Satpathy, M Schniederjan, A Smith, C Smith, BE Thomas, R Vaizer, KK Yeo, MK Bhasin, DH Munn	09/16/2023
Children's Oncology Group's 2023 blueprint for research: Central nervous system tumors Pediatric Blood & Cancer	SES Leary, A Onar-Thomas, J Fangusaro, NG Gottardo, K Cohen, A Smith, A Huang, D Haas-Kogan, M Fouladi	08/03/2023
Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047) Neuro-Oncology	M Monje, T Cooney, J Glod, J Huang, CJ Peer, D Faury, P Baxter, K Kramer, A Lenzen, NJ Robison, L Kilburn, A Vinitsky, WD Figg, N Jabado, M Fouladi, J Fangusaro, A Onar-Thomas, IJ Dunkel, KE Warren	08/01/2023
Evaluating Focal Areas of Signal Intensity (FASI) in Children with Neurofibromatosis Type-1 (NF1) Treated with Selumetinib on Pediatric Brain Tumor Consortium (PBTC)-029B Cancers	N Pillay-Smiley, J Leach, A Lane, T Hummel, J Fangusaro, P de Blank	03/31/2023
The children's brain tumor network (CBTN) - Accelerating research in pediatric central nervous system tumors through collaboration and open science Neoplasia	JV Lilly, JL Rokita, JL Mason, T Patton, S Stefankiewiz, D Higgins, G Trooskin, CA Larouci, K Arya, E Appert, AP Heath, Y Zhu, MA Brown, B Zhang, BK Farrow, S Robins, AM Morgan, TQ Nguyen, E Frenkel, K Lehmann, E Drake, C Sullivan, A Plisiewicz, N Coleman, L Patterson, M Koptyra, Z Helili, N Van Kuren, N Young, MC Kim, C Friedman, A Lubneuski, C Blackden, M Williams, V Baubet, L Tauhid, J Galanaugh, K Boucher, H Ijaz, KA Cole, N Choudhari, M Santi, RW Moulder, J Waller, W Rife, SJ Diskin, M Mateos, DW Parsons, IF Pollack, S Goldman, S Leary, C Caporalini, AM Buccoliero, M Scagnet, D Haussler, D Hanson, R Firestein, J Cain, JJ Phillips, N Gupta, S Mueller, G Grant, M Monje-Deisseroth, S Partap, JP Greenfield, R Hashizume, A Smith, S Zhu, JM Johnston, JR Fangusaro, M Miller, MD Wood, S Gardner, CL Carter, LM Prolo, J Pisapia, K Pehlivan, A Franson, T Niazi, J Rubin, M Abdelbaki, DS Ziegler, HB Lindsay, AG Stucklin, N Gerber, OM Vaske, C Quinsey, BR Rood, J Nazarian, E Raabe, EM Jackson, S Stapleton, RM Lober, DE Kram, C Koschmann, PB Storm, RR Lulla, M Prados, AC Resnick, AJ Waanders	11/03/2022
Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors European Journal of Cancer	AD Pearson, C Allen, J Fangusaro, C Hutter, O Witt, S Weiner, G Reaman, M Russo, P Bandopadhayay, S Ahsan, A Barone, E Barry, T de Rojas, M Fisher, E Fox, JG Bender, L Gore, D Hargrave, D Hawkins, B Kreider, AJ Langseth, G Lesa, F Ligas, M Marotti, LV Marshall, K Nasri, K Norga, K Nysom, A Pappo, G Rossato, N Scobie, M Smith, E Stieglitz, B Weigel, A Weinstein, R Viana, D Karres, G Vassal	10/14/2022
Nervous system (NS) Tumors in Cancer Predisposition Syndromes Neurotherapeutics	P Patil, BB Pencheva, VM Patil, J Fangusaro	09/02/2022
Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors JCO Precision Oncology	M Dankner, Y Wang, R Fazelzad, B Johnson, CA Nebhan, I Dagogo-Jack, NJ Myall, G Richtig, JWP Bracht, M Gerlinger, E Shinozaki, T Yoshino, D Kotani, JR Fangusaro, O Gautschi, J Mazieres, JA Sosman, S Kopetz, V Subbiah, MA Davies, AL Groover, RJ Sullivan, KT Flaherty, DB Johnson, A Benedetti, DW Cescon, A Spreafico, G Zogopoulos, AAN Rose	08/01/2022
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus Neuro-Oncology	PMK de Blank, AM Gross, S Akshintala, JO Blakeley, G Bollag, A Cannon, E Dombi, J Fangusaro, BD Gelb, D Hargrave, A Kim, LJ Klesse, M Loh, S Martin, C Moertel, R Packer, JM Payne, KA Rauen, JJ Rios, N Robison, EK Schorry, K Shannon, DA Stevenson, E Stieglitz, NJ Ullrich, KS Walsh, BD Weiss, PL Wolters, K Yohay, ME Yohe, BC Widemann, MJ Fisher	07/05/2022
Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care JCO Precision Oncology	RJ Summers, SM Castellino, CC Porter, TJ MacDonald, GD Basu, S Szelinger, MK Bhasin, T Cash, AB Carter, RC Castellino, JR Fangusaro, SG Mitchell, MG Pauly, B Pencheva, DS Wechsler, DK Graham, KC Goldsmith	05/01/2022
Imaging response assessment for CNS germ cell tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group and North American Children's Oncology Group The Lancet Oncology	G Morana, D Shaw, SM MacDonald, C Alapetite, T Ajithkumar, A Bhatia, H Brisse, C Jaimes, T Czech, G Dhall, J Fangusaro, C Faure-Conter, M Fouladi, D Hargrave, JH Harreld, D Mitra, JC Nicholson, M Souweidane, B Timmermann, G Calaminus, U Bartels, B Bison, MJ Murray	04/27/2022
Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study Neuro-Oncology	JR Fangusaro, A Onar-Thomas, TY Poussaint, S Wu, AH Ligon, NI Lindeman, A Banerjee, R Packer, LB Kilburn, IF Pollack, IA Qaddoumi, PG Fisher, G Dhall, PA Baxter, SG Kreissman, LA Doyle, MA Smith, M Fouladi, IJ Dunkel	03/21/2022
Pattern of treatment failures in patients with central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pooled analysis of clinical trials Neuro-Oncology	A Fonseca, C Faure-Conter, MJ Murray, J Fangusaro, S Bailey, S Goldman, S Khatua, D Frappaz, G Calaminus, G Dhall, JC Nicholson, E Bouffet, U Bartels	02/24/2022
A Phase 2 Trial of Response-Based Radiation Therapy for Localized Central Nervous System Germ Cell Tumors: Patterns of Failure and Radiation Dosimetry for Nongerminomatous Germ Cell Tumors International Journal of Radiation OncologyBiologyPhysics	ES Murphy, G Dhall, J Fangusaro, U Bartels, M Fouladi, D Shaw, S Khatua, CW Hughes, A Panigraphy, M Ioakeim-Ioannidou, M Souweidane, D Morris, A Gajjar, S Wu, A Onar-Thomas, DA Haas-Kogan, SM MacDonald	01/03/2022
Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children’s Oncology Group study Neuro-Oncology	U Bartels, A Onar-Thomas, SK Patel, D Shaw, J Fangusaro, G Dhall, M Souweidane, A Bhatia, L Embry, CL Trask, ES Murphy, S MacDonald, S Wu, JM Boyett, S Leary, M Fouladi, A Gajjar, S Khatua	11/26/2021
Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms Journal of Clinical Oncology	HS Sabnis, DS Shulman, B Mizukawa, N Bouvier, A Zehir, J Fangusaro, VA Fabrizio, C Whitlow, M Winchester, L Agresta, B Turpin, DS Wechsler, SG DuBois, J Glade-Bender, SM Castellino, N Shukla	09/30/2021
Phase 2 Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors Frontiers in Oncology	J Fangusaro, MG Cefalo, ML Garré, LV Marshall, M Massimino, B Benettaib, N Biserna, J Poon, J Quan, E Conlin, J Lewandowski, M Simcock, N Jeste, DR Hargrave, F Doz, KE Warren	06/08/2021
A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study Neuro-Oncology	J Fangusaro, A Onar-Thomas, TY Poussaint, S Wu, AH Ligon, N Lindeman, O Campagne, A Banerjee, S Gururangan, LB Kilburn, S Goldman, I Qaddoumi, P Baxter, G Vezina, C Bregman, Z Patay, JY Jones, CF Stewart, MJ Fisher, LA Doyle, M Smith, IJ Dunkel, M Fouladi	02/23/2021
Neonatal Central Nervous System Tumors Clinics in Perinatology	S Shahab, J Fangusaro	01/12/2021
Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib Clinical Pharmacokinetics	O Campagne, KK Yeo, J Fangusaro, CF Stewart	12/23/2020
Advances in the classification and treatment of pediatric brain tumors Current Opinion in Pediatrics	J Fangusaro, P Bandopadhayay	12/04/2020
Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: A Pediatric Brain Tumor Consortium trial Pediatric Blood & Cancer	J Fangusaro, DA Mitchell, M Kocak, GW Robinson, PA Baxter, EI Hwang, J Huang, A Onar-Thomas, IJ Dunkel, M Fouladi, KE Warren	10/07/2020
Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group The Lancet Oncology	J Fangusaro, O Witt, P Hernáiz Driever, AK Bag, P de Blank, N Kadom, L Kilburn, RM Lober, NJ Robison, MJ Fisher, RJ Packer, T Young Poussaint, L Papusha, S Avula, AA Brandes, E Bouffet, D Bowers, A Artemov, M Chintagumpala, D Zurakowski, M van den Bent, B Bison, KW Yeom, W Taal, KE Warren	06/01/2020
The “Risk” in Pediatric Low-Grade Glioma Cancer Cell	J Fangusaro, P Bandopadhayay	04/01/2020
Pineoblastoma in children less than six years of age: The Head Start I, II, and III experience Pediatric Blood & Cancer	MS Abdelbaki, MH Abu-Arja, TB Davidson, JR Fangusaro, JR Stanek, IJ Dunkel, G Dhall, SL Gardner, JL Finlay	03/18/2020
Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference Neuro-Oncology	RJ Packer, A Iavarone, DTW Jones, JO Blakeley, E Bouffet, MJ Fisher, E Hwang, C Hawkins, L Kilburn, T MacDonald, SM Pfister, B Rood, FJ Rodriguez, U Tabori, V Ramaswamy, Y Zhu, J Fangusaro, SA Johnston, DH Gutmann	02/12/2020
Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study Acta Neuropathologica	BK Li, A Vasiljevic, C Dufour, F Yao, BLB Ho, M Lu, EI Hwang, S Gururangan, JR Hansford, M Fouladi, S Nobusawa, A Laquerriere, MB Delisle, J Fangusaro, F Forest, H Toledano, P Solano-Paez, S Leary, D Birks, LM Hoffman, A Szathmari, C Faure-Conter, X Fan, D Catchpoole, L Zhou, KAP Schultz, K Ichimura, G Gauchotte, N Jabado, C Jones, D Loussouarn, K Mokhtari, A Rousseau, DS Ziegler, S Tanaka, SL Pomeroy, A Gajjar, V Ramaswamy, C Hawkins, RG Grundy, DA Hill, E Bouffet, A Huang, A Jouvet	12/09/2019
Phase II Trial of Response-Based Radiation Therapy for Patients With Localized CNS Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study Journal of Clinical Oncology	J Fangusaro, S Wu, S MacDonald, E Murphy, D Shaw, U Bartels, S Khatua, M Souweidane, HM Lu, D Morris, A Panigrahy, A Onar-Thomas, M Fouladi, A Gajjar, G Dhall	09/23/2019
A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor Cancer Cell	P Sin-Chan, I Mumal, T Suwal, B Ho, X Fan, I Singh, Y Du, M Lu, N Patel, J Torchia, D Popovski, M Fouladi, P Guilhamon, JR Hansford, S Leary, LM Hoffman, JM Mulcahy Levy, A Lassaletta, P Solano-Paez, E Rivas, A Reddy, GY Gillespie, N Gupta, TE Van Meter, H Nakamura, TT Wong, YS Ra, SK Kim, L Massimi, RG Grundy, J Fangusaro, D Johnston, J Chan, L Lafay-Cousin, EI Hwang, Y Wang, D Catchpoole, J Michaud, B Ellezam, R Ramanujachar, H Lindsay, MD Taylor, CE Hawkins, E Bouffet, N Jabado, SK Singh, CL Kleinman, D Barsyte-Lovejoy, XN Li, PB Dirks, CY Lin, SC Mack, JN Rich, A Huang	07/01/2019
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial The Lancet Oncology	J Fangusaro, A Onar-Thomas, T Young Poussaint, S Wu, AH Ligon, N Lindeman, A Banerjee, RJ Packer, LB Kilburn, S Goldman, IF Pollack, I Qaddoumi, RI Jakacki, PG Fisher, G Dhall, P Baxter, SG Kreissman, CF Stewart, DTW Jones, SM Pfister, G Vezina, JS Stern, A Panigrahy, Z Patay, B Tamrazi, JY Jones, SS Haque, DS Enterline, S Cha, MJ Fisher, LA Doyle, M Smith, IJ Dunkel, M Fouladi	05/28/2019
Improved neuropsychological outcomes following proton therapy relative to X-ray therapy for pediatric brain tumor patients Neuro-Oncology	JP Gross, S Powell, F Zelko, W Hartsell, S Goldman, J Fangusaro, RR Lulla, NP Smiley, JH Chang, V Gondi	04/11/2019
Transcriptional repressor REST drives lineage stage–specific chromatin compaction at Ptch1 and increases AKT activation in a mouse model of medulloblastoma Science Signaling	THW Dobson, RH Tao, J Swaminathan, S Maegawa, S Shaik, J Bravo-Alegria, A Sharma, B Kennis, Y Yang, K Callegari, AR Haltom, P Taylor, M Kogiso, L Qi, S Khatua, S Goldman, RR Lulla, J Fangusaro, TJ MacDonald, XN Li, C Hawkins, V Rajaram, V Gopalakrishnan	01/22/2019